Today is July 01, 2024. All times in Eastern Daylight Time.
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
06/02/2024 - 09:30 AM
BUSINESS WIRE
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
06/02/2024 - 09:00 AM
BUSINESS WIRE
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
06/02/2024 - 08:30 AM
BUSINESS WIRE
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
06/02/2024 - 08:30 AM
BUSINESS WIRE
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
06/02/2024 - 08:05 AM
BUSINESS WIRE
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
06/02/2024 - 08:00 AM
BUSINESS WIRE
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
06/02/2024 - 08:00 AM
BUSINESS WIRE
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
06/02/2024 - 08:00 AM
BUSINESS WIRE
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the United States and Europe
06/02/2024 - 08:00 AM
BUSINESS WIRE
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
06/02/2024 - 08:00 AM
BUSINESS WIRE
1
...
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
« Previous
Next »